Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Eldar Peretz"'
Autor:
Tal Noy-Porat, Efi Makdasi, Ron Alcalay, Adva Mechaly, Yinon Levy, Adi Bercovich-Kinori, Ayelet Zauberman, Hadas Tamir, Yfat Yahalom-Ronen, Ma’ayan Israeli, Eyal Epstein, Hagit Achdout, Sharon Melamed, Theodor Chitlaru, Shay Weiss, Eldar Peretz, Osnat Rosen, Nir Paran, Shmuel Yitzhaki, Shmuel C. Shapira, Tomer Israely, Ohad Mazor, Ronit Rosenfeld
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-7 (2020)
Here, Noy-Porat, Makdasi et al. report the isolation of a panel of neutralizing mAbs selected against SARS-CoV-2 receptor-binding domain (RBD) from a phage display library constructed based on patient samples collected in the acute phase of the disea
Externí odkaz:
https://doaj.org/article/b2261c0965d74199a91b395d6e6b9e4c
Autor:
Tal Noy-Porat, Ron Alcalay, Adva Mechaly, Eldar Peretz, Efi Makdasi, Ronit Rosenfeld, Ohad Mazor
Publikováno v:
STAR Protocols, Vol 2, Iss 4, Pp 100836- (2021)
Summary: This protocol describes the use of a biolayer interferometry platform for assessing antibody-antigen interactions. The protocol focuses on affinity determination and epitope binning, although the system can be utilized for measuring any prot
Externí odkaz:
https://doaj.org/article/1e82332e983d496badbbc1c03ca139a7
Autor:
Yinon Levy, Ron Alcalay, Anat Zvi, Efi Makdasi, Eldar Peretz, Tal Noy-Porat, Theodor Chitlaru, Michal Mandelboim, Ohad Mazor, Ronit Rosenfeld
Publikováno v:
Vaccines, Vol 10, Iss 2, p 251 (2022)
SARS-CoV-2 surface spike protein mediates the viral entry into the host cell and represents the primary immunological target of COVID-19 vaccines as well as post-exposure immunotherapy. Establishment of the highly immunogenic B-cell epitope profile o
Externí odkaz:
https://doaj.org/article/f6d874276ff7471bb333a002d4ea3bbb
Autor:
Efi Makdasi, Yinon Levy, Ron Alcalay, Tal Noy-Porat, Eran Zahavy, Adva Mechaly, Eyal Epstein, Eldar Peretz, Hila Cohen, Liat Bar-On, Theodor Chitlaru, Ofer Cohen, Itai Glinert, Hagit Achdout, Tomer Israely, Ronit Rosenfeld, Ohad Mazor
Publikováno v:
Viruses, Vol 13, Iss 4, p 566 (2021)
Monoclonal antibodies represent an important avenue for COVID-19 therapy and are routinely used for rapid and accessible diagnosis of SARS-CoV-2 infection. The recent emergence of SARS-CoV-2 genetic variants emphasized the need to enlarge the reperto
Externí odkaz:
https://doaj.org/article/2163f4679194436f87e63d7c590eccca
Autor:
Efi Makdasi, Anat Zvi, Ron Alcalay, Tal Noy-Porat, Eldar Peretz, Adva Mechaly, Yinon Levy, Eyal Epstein, Theodor Chitlaru, Ariel Tennenhouse, Moshe Aftalion, David Gur, Nir Paran, Hadas Tamir, Oren Zimhony, Shay Weiss, Michal Mandelboim, Ella Mendelson, Neta Zuckerman, Ital Nemet, Limor Kliker, Shmuel Yitzhaki, Shmuel C. Shapira, Tomer Israely, Sarel J. Fleishman, Ohad Mazor, Ronit Rosenfeld
SummaryA wide range of SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) were reported to date, most of which target the spike glycoprotein and in particular its receptor binding domain (RBD) and N-terminal domain (NTD) of the S1 subunit. The ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::789ed4fb666275639bf492f03e1ad2cb
https://doi.org/10.1101/2021.04.01.438035
https://doi.org/10.1101/2021.04.01.438035
Autor:
Eran Zahavy, Tal Noy-Porat, Theodor Chitlaru, Hila Cohen, Eyal Epstein, Itai Glinert, Adva Mechaly, Ofer Cohen, Yinon Levy, Ronit Rosenfeld, Ohad Mazor, Tomer Israely, Efi Makdasi, Ron Alcalay, Hagit Achdout, Liat Bar-On, Eldar Peretz
Publikováno v:
Viruses
Volume 13
Issue 4
Viruses, Vol 13, Iss 566, p 566 (2021)
Volume 13
Issue 4
Viruses, Vol 13, Iss 566, p 566 (2021)
Monoclonal antibodies represent an important avenue for COVID-19 therapy and are routinely used for rapid and accessible diagnosis of SARS-CoV-2 infection. The recent emergence of SARS-CoV-2 genetic variants emphasized the need to enlarge the reperto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9baffb81dc4201475487c19ef15c7e97
Autor:
Tal Noy-Porat, Efi Makdasi, Ron Alcalay, Adva Mechaly, Yinon Levy, Adi Bercovich-Kinori, Ayelet Zauberman, Hadas Tamir, Yfat Yahalom-Ronen, Ma’ayan Israeli, Eyal Epstein, Hagit Achdout, Sharon Melamed, Theodor Chitlaru, Shay Weiss, Eldar Peretz, Osnat Rosen, Nir Paran, Shmuel Yitzhaki, Shmuel C. Shapira, Tomer Israely, Ohad Mazor, Ronit Rosenfeld
The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Thus far, there is no approved therapeutic drug, specifically targeting this emerging virus. Here we report the isolation and characterizatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fa006ef52848ee93a84b4825eb4803d
https://doi.org/10.1101/2020.05.20.106609
https://doi.org/10.1101/2020.05.20.106609
Autor:
Adi Bercovich-Kinori, Hadas Tamir, Ayelet Zauberman, Efi Makdasi, Eyal Epstein, Osnat Rosen, Adva Mechaly, Shay Weiss, Theodor Chitlaru, Hagit Achdout, Tomer Israely, Tal Noy-Porat, Yfat Yahalom-Ronen, Nir Paran, Yinon Levy, Ronit Rosenfeld, Shmuel C. Shapira, Shmuel Yitzhaki, Sharon Melamed, Ohad Mazor, Ron Alcalay, Ma'ayan Israeli, Eldar Peretz
Publikováno v:
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-7 (2020)
Nature Communications, Vol 11, Iss 1, Pp 1-7 (2020)
The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically targeting this emerging virus. Here we report the isolation and characterization
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c88ba30143214d3d7224c8e81e47123
https://pubmed.ncbi.nlm.nih.gov/32855401
https://pubmed.ncbi.nlm.nih.gov/32855401
Autor:
Yinon Levy, Ron Alcalay, Anat Zvi, Efi Makdasi, Eldar Peretz, Tal Noy-Porat, Theodor Chitlaru, Michal Mandelboim, Ohad Mazor, Ronit Rosenfeld
Publikováno v:
Vaccines; Volume 10; Issue 2; Pages: 251
SARS-CoV-2 surface spike protein mediates the viral entry into the host cell and represents the primary immunological target of COVID-19 vaccines as well as post-exposure immunotherapy. Establishment of the highly immunogenic B-cell epitope profile o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e13b406c42a73e1d5d47439317964b3f
Autor:
Ron Alcalay, Shmuel C. Shapira, Moshe Aftalion, Tal Noy-Porat, Ella Mendelson, Limor Kliker, Nir Paran, Efi Makdasi, Michal Mandelboim, Eldar Peretz, Eyal Epstein, Sarel J. Fleishman, Ohad Mazor, Tomer Israely, Ariel Tennenhouse, Adva Mechaly, Theodor Chitlaru, Shay Weiss, Hadas Tamir, Yinon Levy, Shmuel Yitzhaki, Neta S. Zuckerman, David Gur, Ital Nemet, Ronit Rosenfeld, Oren Zimhony, Anat Zvi
Publikováno v:
Cell Reports
A wide range of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing monoclonal antibodies (mAbs) have been reported, most of which target the spike glycoprotein. Therapeutic implementation of these antibodies has been challenged
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::990e3d1e146b530815866d7ca4637aa8